AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20579357 — intervention group
Group type: COMPARATOR
Intervention: Conventional fertility care only (control group).
Number of subjects: 0
Study 19137767 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 1373
Study 19137767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1373
Study 16365119 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery
Number of subjects: 20
Study 16365119 — intervention group
Group type: COMPARATOR
Intervention: Conventional instrumentation
Number of subjects: 20
Study 14576501 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 0.5 g t.i.d. intravenously
Number of subjects: 176
Study 14576501 — intervention group
Group type: COMPARATOR
Intervention: Imipenem 0.5 g q.i.d. intravenously
Number of subjects: 176
Study 10756289 — intervention group
Group type: EXPERIMENTAL
Intervention: Subepithelial connective tissue graft
Number of subjects: 24
Study 10756289 — intervention group
Group type: EXPERIMENTAL
Intervention: Free full-thickness gingival graft
Number of subjects: 24
Study 10756289 — intervention group
Group type: COMPARATOR
Intervention: Control group (unoperated defects)
Number of subjects: 24
Study 9133860 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone sodium phosphate and lidocaine hydrochloride
Number of subjects: 27
Study 9133860 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine hydrochloride
Number of subjects: 27
Study 9133860 — intervention group
Group type: COMPARATOR
Intervention: pH-buffered saline (placebo)
Number of subjects: 27
Study 1345218 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol 50 mg once daily
Number of subjects: 100
Study 1345218 — intervention group
Group type: COMPARATOR
Intervention: co‐amiloride 25 mg + amiloride 5 mg once daily
Number of subjects: 100
Study 1345218 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 100
Study 3909456 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (Flagyl; Maybaker)
Number of subjects: 48
Study 3909456 — intervention group
Group type: COMPARATOR
Intervention: Tinidazole (Fasigyn; Pfizer)
Number of subjects: 48
Study 31860104 — intervention group
Group type: EXPERIMENTAL
Intervention: STAT-ED intervention (motivational interviewing)
Number of subjects: 168
Study 31860104 — intervention group
Group type: COMPARATOR
Intervention: EUC (enhanced usual care)
Number of subjects: 168
Study 29414827 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins at baseline
Number of subjects: 1061
Study 29414827 — intervention group
Group type: EXPERIMENTAL
Intervention: No statins at baseline
Number of subjects: 1061
Study 29414827 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 1061
Study 29414827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1061
Study 27288618 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled sodium heparin (5000 units in 2 mL) nebulization four times daily
Number of subjects: 214
Study 27288618 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 214
Study 27288618 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled sodium chloride (0.9% sodium chloride, 2 mL) nebulization four times daily
Number of subjects: 214
Study 26184173 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined workout group (CWG) - combined endurance/resistance workout (20 min on a bicycle ergometer, followed by 20 min of resistance training)
Number of subjects: 28
Study 26184173 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance workout group (EWG) - 40 min endurance training program
Number of subjects: 28
Study 21632438 — intervention group
Group type: EXPERIMENTAL
Intervention: Distressing high-resolution color images
Number of subjects: 0
Study 21632438 — intervention group
Group type: COMPARATOR
Intervention: Less distressing two-color images with degraded outline and detail
Number of subjects: 0
Study 20646373 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic dissector (UAS)
Number of subjects: 2736
Study 20646373 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique (CT)
Number of subjects: 2736
Study 18818847 — intervention group
Group type: EXPERIMENTAL
Intervention: In-shower body lotion product form
Number of subjects: 0
Study 18818847 — intervention group
Group type: COMPARATOR
Intervention: Control exposure method
Number of subjects: 0
Study 15956130 — intervention group
Group type: COMPARATOR
Intervention: 0 Gy (placebo)
Number of subjects: 99
Study 15956130 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 Gy
Number of subjects: 99
Study 15956130 — intervention group
Group type: EXPERIMENTAL
Intervention: 10.5 Gy
Number of subjects: 99
Study 15956130 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 Gy
Number of subjects: 99
Study 11834994 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamed intramedullary nailing
Number of subjects: 20
Study 11834994 — intervention group
Group type: COMPARATOR
Intervention: Unreamed intramedullary nailing
Number of subjects: 20
Study 10369587 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative lens-sparing (RLS) technique
Number of subjects: 42
Study 10369587 — intervention group
Group type: COMPARATOR
Intervention: Modified lateral beam (MLB) technique
Number of subjects: 42
Study 7595716 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF 4 micrograms/kg subcutaneously from days 5 to 14
Number of subjects: 20
Study 7595716 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF in the second cycle of PFL
Number of subjects: 20
Study 7595716 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF treatment
Number of subjects: 20
Study 7595716 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 20
Study 2073486 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% with epinephrine
Number of subjects: 43
Study 2073486 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.75% with epinephrine
Number of subjects: 43
Study 728485 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent feedback (CF)
Number of subjects: 0
Study 728485 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontingent (yoked) feedback (YF)
Number of subjects: 0
Study 728485 — intervention group
Group type: COMPARATOR
Intervention: No feedback (NF)
Number of subjects: 0
Study 31950267 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (group S) at 0.5, 1.0, and 1.5 MAC
Number of subjects: 24
Study 31950267 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (group P) at Ce of 4 μg/ml
Number of subjects: 24
Study 31950267 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (group P) at Ce of 2 or 3 μg/ml
Number of subjects: 24
Study 31950267 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane and Propofol at clinical concentrations
Number of subjects: 24
Study 31097405 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide, bortezomib, and dexamethasone
Number of subjects: 559
Study 31097405 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib and dexamethasone
Number of subjects: 559
Study 27346437 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 150-300 mg/day
Number of subjects: 82
Study 27346437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 26447156 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline supplementation (500 mg daily for 9 months)
Number of subjects: 60
Study 26447156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 23517797 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control (target HbA1c < 6.5%)
Number of subjects: 23182
Study 23517797 — intervention group
Group type: COMPARATOR
Intervention: Conventional glycemic control (target HbA1c > 6.4%)
Number of subjects: 23182
Study 18317601 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal tube cuffs filled with alkalinized lidocaine (2% lidocaine plus 8.4% sodium bicarbonate)
Number of subjects: 50
Study 18317601 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube cuffs filled with air
Number of subjects: 50
Study 15330679 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol/levonorgestrel (4.4/2.74 and 4.5/3.75mg)
Number of subjects: 0
Study 15330679 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol/levonorgestrel (4.4/1.39 [approved dosage], 4.4/2.74, and 4.5/3.75mg)
Number of subjects: 0
Study 15330679 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol/levonorgestrel
Number of subjects: 0
Study 15330679 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol/levonorgestrel (4.4/1.39mg)
Number of subjects: 0
Study 15330679 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol/levonorgestrel and estradiol
Number of subjects: 0
Study 15330679 — intervention group
Group type: COMPARATOR
Intervention: Estradiol/levonorgestrel, estradiol, and placebo
Number of subjects: 0
Study 11130523 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitors (placebo-controlled trials)
Number of subjects: 12352
Study 11130523 — intervention group
Group type: COMPARATOR
Intervention: Calcium antagonists (placebo-controlled trials)
Number of subjects: 12352
Study 11130523 — intervention group
Group type: EXPERIMENTAL
Intervention: More intensive blood-pressure-lowering strategies
Number of subjects: 12352
Study 11130523 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-antagonist-based therapy
Number of subjects: 12352
Study 9491722 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (Cardura)
Number of subjects: 20
Study 9491722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8255408 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of the partial 5‐HT1A agonist ipsapirone
Number of subjects: 60
Study 8255408 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to cold ambient temperature (5 degrees C) and placebo
Number of subjects: 60
Study 8255408 — intervention group
Group type: COMPARATOR
Intervention: Exposure to normal ambient temperature (28 degrees C) and placebo
Number of subjects: 60
Study 2862819 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous aminophylline
Number of subjects: 40
Study 2862819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30019249 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/day)
Number of subjects: 1734
Study 30019249 — intervention group
Group type: EXPERIMENTAL
Intervention: Minodronate (1 mg/day or 50 mg/4 weeks)
Number of subjects: 1734
Study 30019249 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 1734
Study 29099521 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g FDSP
Number of subjects: 60
Study 29099521 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g FDSP
Number of subjects: 60
Study 29099521 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 26518728 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine administration
Number of subjects: 2
Study 26518728 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 2
Study 25079979 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS over the primary motor cortex of the lower leg (M1-LL)
Number of subjects: 20
Study 25079979 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS over the dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 20
Study 25079979 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study 22270787 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic Regression (LR) analysis
Number of subjects: 140
Study 22270787 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (ANN)
Number of subjects: 140
Study 22270787 — intervention group
Group type: COMPARATOR
Intervention: Five breast radiologists
Number of subjects: 140
Study 19566902 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin serotype B (BoNT/B) injections into the masseter muscles
Number of subjects: 11
Study 19566902 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 11
Study 17350783 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard information and a newly written extended information brochure about risks in connection with cardiac surgery (Intervention group)
Number of subjects: 99
Study 17350783 — intervention group
Group type: COMPARATOR
Intervention: Standard information (Control group)
Number of subjects: 99
Study 15357646 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a 12 MIU (44 microg) administered three times weekly
Number of subjects: 267
Study 15357646 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a 24 MIU (88 microg) administered three times weekly
Number of subjects: 267
Study 15357646 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a 12 MIU (44 microg) administered daily
Number of subjects: 267
Study 15357646 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a 24 MIU (88 microg) administered daily
Number of subjects: 267
Study 15357646 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a
Number of subjects: 267
Study 15357646 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a in Chinese patients
Number of subjects: 267
Study 11248171 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled grafts
Number of subjects: 84
Study 11248171 — intervention group
Group type: COMPARATOR
Intervention: Sewn grafts
Number of subjects: 84
Study 9833848 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir monotherapy (200, 400, or 600 mg every 8 h daily, or 300 mg every 12 h daily)
Number of subjects: 79
Study 9833848 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir-ZDV combination therapy (600 mg ZDV)
Number of subjects: 79
Study 7805984 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% testosterone propionate
Number of subjects: 58
Study 7805984 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum ointment
Number of subjects: 58
Study 2633019 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tramadol 100 mg and lorazepam 1 mg (Group A)
Number of subjects: 200
Study 2633019 — intervention group
Group type: COMPARATOR
Intervention: Flunitrazepam 1 mg (Group B)
Number of subjects: 200
Study 241602 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 29
Study 241602 — intervention group
Group type: EXPERIMENTAL
Intervention: Alclofenac
Number of subjects: 29
Study 241602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 31662118 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase
Number of subjects: 433
Study 31342566 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg of lingonberry extract and 30 mg of amla fruit extract
Number of subjects: 99
Study 31342566 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of lingonberry extract and 60 mg of amla fruit extract
Number of subjects: 99
Study 31342566 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 99
Study 28065436 — intervention group
Group type: EXPERIMENTAL
Intervention: SE-PMMA IOL
Number of subjects: 94
Study 25375836 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (5-20 mg/d)
Number of subjects: 217
Study 23815124 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin 0.4% ointment (375 mg applied anally every 12 hours for 21 days)
Number of subjects: 247
Study 23815124 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment (375 mg applied anally every 12 hours for 21 days)
Number of subjects: 247
Study 21774823 — intervention group
Group type: EXPERIMENTAL
Intervention: Seclusion (minimally furnished seclusion room with open but barred windows onto the nursing station)
Number of subjects: 0
Study 21774823 — intervention group
Group type: COMPARATOR
Intervention: Mechanical restraints (strong cotton banding to edge of bed with medications as indicated and close observation)
Number of subjects: 0
Study 19789597 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone
Number of subjects: 10
Study 16883264 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (Q) at an average dose of 13 mg/day (n=28)
Number of subjects: 80
Study 16883264 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (V) at a dose of 121 mg/day (n=26)
Number of subjects: 80
Study 16883264 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Quinapril and Valsartan (Q+V) at doses of 12 mg/day and 78 mg/day respectively (n=26)
Number of subjects: 80
Study 16883264 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (Q)
Number of subjects: 80
Study 16883264 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (V)
Number of subjects: 80
Study 15054339 — intervention group
Group type: EXPERIMENTAL
Intervention: Strictly adherent (SA) group
Number of subjects: 163
Study 15054339 — intervention group
Group type: COMPARATOR
Intervention: Not strictly adherent (NSA) group
Number of subjects: 163
Study 15054339 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SA and NSA groups
Number of subjects: 163
Study 15054339 — intervention group
Group type: EXPERIMENTAL
Intervention: SA subjects
Number of subjects: 163
Study 11408125 — intervention group
Group type: EXPERIMENTAL
Intervention: PMMA intraocular lens (IOL) implantation
Number of subjects: 300
Study 11408125 — intervention group
Group type: COMPARATOR
Intervention: Silicone intraocular lens (IOL) implantation
Number of subjects: 300
Study 11408125 — intervention group
Group type: COMPARATOR
Intervention: Acrylic intraocular lens (IOL) implantation
Number of subjects: 300
Study 11408125 — intervention group
Group type: COMPARATOR
Intervention: Nd:YAG capsulotomy
Number of subjects: 300
Study 11408125 — intervention group
Group type: COMPARATOR
Intervention: Visual acuity
Number of subjects: 300
Study 9240579 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation >8000 IU daily
Number of subjects: 1508
Study 9240579 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation >10000 IU daily
Number of subjects: 1508
Study 9240579 — intervention group
Group type: COMPARATOR
Intervention: Normal control group (consuming <5000 IU)
Number of subjects: 1508
Study 8214491 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative terfenadine (60 mg) and ranitidine (150 mg) with intra-operative tubocurarine and morphine (group A)
Number of subjects: 60
Study 8214491 — intervention group
Group type: COMPARATOR
Intervention: Pre-operative placebo and intra-operative tubocurarine and morphine (group B)
Number of subjects: 60
Study 8214491 — intervention group
Group type: COMPARATOR
Intervention: Pre-operative placebo and intra-operative fentanyl and vecuronium (group C)
Number of subjects: 60
Study 3623736 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg every 12 hours for 7 days
Number of subjects: 72
Study 3623736 — intervention group
Group type: COMPARATOR
Intervention: Nalidixic acid 500 mg every 8 hours for 7 days
Number of subjects: 72
Study 30539861 — intervention group
Group type: EXPERIMENTAL
Intervention: Endostar continuous intravenous infusion combined with SOX regimen chemotherapy
Number of subjects: 60
Study 30539861 — intervention group
Group type: COMPARATOR
Intervention: SOX regimen chemotherapy alone
Number of subjects: 60
Study 27525830 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity treadmill exercise
Number of subjects: 75
Study 27525830 — intervention group
Group type: COMPARATOR
Intervention: Stretching and toning exercise (Control)
Number of subjects: 75
Study 25026287 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO)
Number of subjects: 260
Study 25026287 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 260
Study 25026287 — intervention group
Group type: EXPERIMENTAL
Intervention: NPM1mut MRD
Number of subjects: 260
Study 25026287 — intervention group
Group type: EXPERIMENTAL
Intervention: WT1 MRD
Number of subjects: 260
Study 23040422 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening followed by intensive multifactorial treatment for people diagnosed with diabetes (n=15)
Number of subjects: 20184
Study 23040422 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening plus routine care of diabetes according to national guidelines (n=13)
Number of subjects: 20184
Study 23040422 — intervention group
Group type: COMPARATOR
Intervention: No screening (control group) (n=5)
Number of subjects: 20184
Study 23040422 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening (general)
Number of subjects: 20184
Study 20542931 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised bladder rehabilitation programme (n=40)
Number of subjects: 74
Study 20542931 — intervention group
Group type: COMPARATOR
Intervention: Control waitlist group (n=34)
Number of subjects: 74
Study 18182412 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 0
Study 18182412 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin plus gentamicin
Number of subjects: 0
Study 15972025 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary bypass surgery
Number of subjects: 14
Study 15972025 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 14
Study 12563578 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerine (SL NTG) plus 1 mg of lorazepam intravenously (Group 2)
Number of subjects: 27
Study 12563578 — intervention group
Group type: COMPARATOR
Intervention: Sublingual nitroglycerine (SL NTG) alone (Group 1)
Number of subjects: 27
Study 11111384 — intervention group
Group type: COMPARATOR
Intervention: BVCM (bleomycin, vincristine, methotrexate, plus cisplatin)
Number of subjects: 38
Study 11111384 — intervention group
Group type: EXPERIMENTAL
Intervention: BVM (bleomycin, vincristine, methotrexate)
Number of subjects: 38
Study 9006788 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ibuprofen (ibugel, 3 x 375 mg daily)
Number of subjects: 17
Study 9006788 — intervention group
Group type: COMPARATOR
Intervention: Oral ibuprofen (2 x 600 mg daily)
Number of subjects: 17
Study 1298490 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning stimulation paradigm
Number of subjects: 0
Study 1298490 — intervention group
Group type: COMPARATOR
Intervention: Long, random, and self-triggered stimulation paradigms
Number of subjects: 0
Study 6832623 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pain (test stimulus: repeated one minute immersions of a hand into ice water, 20 minutes total)
Number of subjects: 9